NCT06297655 - A Clinical Study of Recombinant Human Coagulation Factor VIII for Injection in Patients With Severe Hemophilia A | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 30, 2024

Primary Completion Date

April 30, 2025

Study Completion Date

April 30, 2025

Conditions

Hemophilia A

Interventions

DRUG

Recombinant human activated coagulation factor VIII for injection

Recombinant human coagulation factor VIII for injection is a recombinant DNA product with functional characteristics comparable to endogenous factor VIII.

Trial Locations (11)

210008

Nanjing Drug Tower Hospital, Nanjing

230002

Anhui Provincial Hospital, Hefei

300020

Hematology Hospital of Chinese Academy of Medical Sciences, Tianjin

330006

Jiangxi Provincial People's Hospital, Nanchang

400010

The Second Affiliated Hospital of Chongqing Medical University, Chongqing

410008

Xiangya Hospital Central South University, Changsha

450003

Henan Tumor Hospital, Zhengzhou

510515

Nanfang Hospital, Southern Medical University, Guangzhou

530021

The First Affiliated Hospital of Guangxi Medical University, Nanning

650106

The Second Affiliated Hospital of Kunming Medical University, Kunming

730013

The First Hospital of Lanzhou University, Lanzhou

All Listed Sponsors

lead

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

INDUSTRY